Provided by HIVandHepatitis.com
Published on Monday, 03 March 2014 00:00
Written by Gregory Fowler
The opening day of the 21st Conference on Rtroviruses and Opportuistic Infections (CROI 2014) featured a press conference on advances in the treatment of hepatitis C, with a focus on how new drugs may be used in the real world, given barriers such as high cost and a shortage of experienced medical providers.
The panel of hepatitis C experts included Douglas Dieterich from Mt. Sinai's Ichan School of Medicine, Trevor Hawkins from the Southwest CARE Center, Anita Kohli from the National Institutes of Health, Daniel Cohen from AbbVie, and Marion Peters form the University of California at San Francisco.
The advent of direct-acting agents (DAAs) has ushered in a new era of hepatitis C treatment. Researchers summarized new data on Gilead Sciences' ledipasvir and sofosbuvir (Sovaldi) -- which Dieterich said has been "flying off the shelves" since its December approval -- Janssen's recently approved simeprevir (Olysio), Boehringer Ingelheim's faldaprevir, Bristol-Myers Squibb's daclatasvir-based oral regimen, and AbbVie's 3-drug oral DAA regimen.
[Hepatitis C press conference at CROI 2014, March 3, 2014]
Opening press conference. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston. March 3, 2014.